

## Understanding and Interpreting Pharmacokinetic (PK) and Pharmacodynamic (PD) Targets for Antimicrobial Dosing

### Back to Basics – a reminder of PK/PD

**PK** describes the movement of drug through the body over time - influenced by its absorption, distribution, metabolism and excretion.


- Physiological factors which can influence this include gastrointestinal conditions, drug/food interactions, renal function, volume of distribution and the site of infection
- Drug factors which can influence this include lipophilicity of the drug, bioavailability and protein binding

**PD** is the study of effect (efficacy and toxicity) once the drug has reached a specified site of action. In the case of antimicrobials this is the ability to kill or inhibit antimicrobial growth once at the site of action.

### Time-dependent versus Concentration-dependent activity

Different antimicrobials have different mechanisms of action and bactericidal activity characteristics. The efficacy of an antimicrobial is determined by a range of factors including activity and duration of effect at the site of infection (known as the PK-PD indice) and MIC as outlined below.

#### The PK-PD indices associated with antibacterial activity



#### Time (%T) > MIC = Time-dependent antimicrobials

Effect depends on duration the unbound drug is at concentrations above the MIC

- Increasing the frequency of dosing or giving via continuous infusion will increase %T > MIC
- Increasing dose to achieve higher concentrations does not result in greater efficacy once it is above the MIC

#### AUC:MIC = Concentration-dependent antimicrobials with time dependence

Effect is related to the AUC of the unbound drug from 0-24 hours and the MIC

#### Cmax:MIC = Concentration-dependent antimicrobials


Greater killing achieved as the ratio of drug concentration (Cmax) to MIC increases within the therapeutic range

- Changing the dose will mainly alter the Cmax:MIC and AUC:MIC ratio
- Larger doses, less frequently improve chances of success

Pharmacodynamic index correlated with maximal efficacy of selected antimicrobials:

Antimicrobial / Class	Effect	Distribution	Excretion	PK/PD parameter
Beta-lactams (includes Carbapenems)	Bactericidal	Low protein binding + hydrophilic	Renal	Time > MIC
Aminoglycosides	Bactericidal	Hydrophilic	Renal	C <sub>max</sub> :MIC & AUC:MIC
Vancomycin	Bactericidal	Hydrophilic	Renal	AUC:MIC
Linezolid	Bacteriostatic	Lipophilic wide distribution	Renal / Non-renal	AUC:MIC
Clindamycin	Bacteriostatic	Lipophilic wide distribution	Hepatobiliary	AUC:MIC
Daptomycin	Bactericidal	Highly protein bound (weak, reversible) + hydrophilic	Renal	C <sub>max</sub> :MIC & AUC:MIC
Fluoroquinolones (e.g. ciprofloxacin)	Bactericidal	Lipophilic wide distribution	Renal & hepatobiliary	C <sub>max</sub> :MIC & AUC:MIC

## Where should we be considering PK/PD?



### References / Further reading:

1. Roberts, JA, Abdul Aziz MH, Lipman J et al. Challenges and Potential Solutions – Individualised Antibiotic Dosing at the Bedside for Critically Ill Patients: a structured review. *Lancet Infect Dis.* 2014 June; 14(6): 498-509.
2. Shah, S, Barton G, Fischer A. Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. *Journal of the Intensive Care Society.* 2015; 16(2):147-153.
3. Antimicrobial Stewardship – From Principles to Practice. British Society for Antimicrobial Chemotherapy (eBook) 2018.

Produced by the Central Adelaide Local Health Network (CALHN) Antimicrobial Stewardship Committee

*Endorsed by the South Australian expert Advisory Group on Antimicrobial Resistance (SAAGAR) June 2018. Last reviewed and amended June 2018. SAAGAR has endeavoured to ensure that the information in this publication is accurate; however, it makes no representation or warranty to this effect. You rely on this publication at your own risk. SAAGAR disclaims all liability for any claims, losses, damages, costs and expenses suffered or incurred as a result of reliance on this publication. As the information in this publication is subject to review, please contact a medical or health professional before using this publication.*